Browse by Medical Category
The Medicine Innovation Program supports and enhances innovation within the Department of Medicine at Massachusetts General Hospital.
Throughout the Department of Medicine, talented faculty are developing innovative, cost-effective technologies that have the potential to significantly impact patient care. The Medicine Innovation Program (MIP) was launched in 2015 to support and advance these innovations. Over the past four years, MIP has provided seed funding to a diverse portfolio of projects in the artificial intelligence and digital health spaces, as well as to the development of novel therapeutics and medical devices. In 2017, MIP launched the ROCK STARt-up Associate Program with Third Rock Ventures, a leading biotechnology venture firm in Boston. This program gives faculty, interested in entrepreneurship, the opportunity to build successful and translational scientific ventures from the ground up. MIP is led by Christiana Iyasere MD, MBA.
Christiana Iyesere, MD, MBA is the director of the Medicine Innovation Program. She is an established leader in developing innovative platforms focused on improving patient care. A graduate of Yale University, Columbia University College of Physicians and Surgeons, and Harvard University Business School, Christiana served as a Howard Hughes Research Fellow in HIV Immunology for the Laboratory of Immunoregulation at the National Institutes of Health. She completed her Internal Medicine Residency at Massachusetts General Hospital and served for a year as an Administrative Fellow alongside Dr. Peter Slavin, leading a series of projects related to optimal technology adoption and utilization. She has served in prominent roles such as Co-Director of the MGH Innovation Support Center; Associate Director of “The Sandbox,” a clinical innovation site; Technology Assessment Coordinator for the Council for Technology, Adoption, Innovation, and Promotion; and Chair of the Mass General Innovation Collaborative. She is a member of the Partners Innovation Council and the Partners Epic Innovation Council. Christiana is also an Assistant Professor of Medicine at Harvard Medical School.
Gabrielle Geonnotti, MPH, is the Program Administrator for the Medicine Innovation Program. She assists with the coordination of the annual RFP and helps support MIP awardees throughout the duration of their grants. Gabrielle graduated from The George Washington University and holds a Master of Public Health degree from The University of Edinburgh. Her masters dissertation focused on priority setting in global child health, shaping her interest in investing in innovative research and technologies. Before joining the Department of Medicine at MGH, she worked in the pharmaceutical industry, recruiting sales teams and later building digital platforms for nurses treating patients with autoimmune diseases.
MIP Advisory Board
Mark Poznansky, MD, PhD Director of the Vaccine and Immunotherapy Center
Kristian Olson, MD, Director, CAMTech
Emy Chan, PhD, Director, Partners HealthCare Innovation
Jeffrey Gelfand, MD, 2015 MIP Awardee
Shaw Warren, MD, Associate Faculty Wyss Institute at Harvard University,
Martha Gray, PhD, Director, Madrid-MIT m+vision consortium
Petra Krauledat, PhD, Principal, PNPResearch Corporation
Peter Hansen, PhD, Principal, PNPResearch Corporation
Larry Miller, MD, MPH, President, Apnimed, Inc.
Eric Isselbacher, MD, Director, Healthcare Transformation Lab
Joshua Metlay, MD, PhD, Chief of the Division of General Internal Medicine
Thomas McCoy, MD, 2017 MIP Awardee
Medicine Innovation Pilot Grant Awards
The Medicine Innovation Pilot Grant Awards take research projects with the potential to transform medicine and provides them with the needed resources to move forward to the next inflection point in successful solution development. Resources provided include structured project management support, milestone based stewardship of resources, focused mentorship and access to networks that can move the project to the next step in development. The goal is to move from a project to a product that can be consumed and used by patients and providers.
MIP actively supports projects for one year to 18 months depending on the needs of the project and project team. Many of MIP’s projects have gone on to attain follow-on grant funding, industry partnerships, or successful adoption into the existing healthcare infrastructure.
ROCK STARt-up Associate Program
The ROCK STARt-Up Associate Program is a 2-year associate program in which MGH DOM faculty will be immersed in the biotech start-up environment at Third Rock Ventures (TRV) in Boston, MA. The Boston Biotech community is one of the most robust in the world and TRV is one of the leading venture capital groups in the country. Consequently, the potential for MGH DOM faculty to actively participate in and build translational opportunities is unparalleled.
TRV has a unique translational model: the group builds companies from the ground up, starting in an area defined by clinical need and scientific opportunity. As a result, they represent an entrepreneurial environment in which MGH DOM faculty can participate in the process of building a successful scientific venture from its early beginnings.
For more information on the Associate experience at 3rd Rock, please visit:
For more information please contact:
Christiana Iyasere, MD, MBA
Director, MGH DOM Medicine Innovation Program (MIP), Rock Star Associate program
Allergy Passport Digital Application for documentation of food allergies Kimberley Blumenthal, MD 2016 Awardee
DreAMLand Digital Application for support of patients with Acute Myeloid Leukemia Areej El-Jawahri, MD 2017 Awardee
PROE PCI Risk assessment for patient and physician prior to cardiac catheterization for improved decision making Jason Wasfy, MD, MPH 2015 Awardee
Clinical Data Visualization and Machine Learning Deep learning to extract useful information for clinical decision making Tom McCoy, MD 2017 Awardee
Natural Language Processing in the Evaluation and Diagnosis of Irritable Bowel Syndrome Kyle Staller, MD, MPH 2018 Awardee
Long Acting Parathyroid Hormone First in class drug for treatment of Hypoparathyroidism Michael Mannstadt, MD, PhD 2015 Awardee
Laser Therapy for Treatment of Resistant Urinary Tract Infections Novel treatment of urinary tract infections with light based therapy Jeffery Gelfand, MD 2015 Awardee
Allergy Tolerance Laser therapy to induce immune tolerance to food allergens Satoshi Kashiwagi, MD, PhD 2016 Awardee
Day Zero Diagnostics Diagnosis of bacterial species and sensitivities within hours Douglas Kwon, MD, PhD 2016 Awardee
Novel Osteoporosis Therapy New oral therapy for osteoperosis Mark Wein, MD, PhD 2017 Awardee
MGH Healthcare Transformation Lab
Massachusetts Institute of Technology IDEA² Global
Duke Translational Research Institute
Third Rock Ventures
The Vaccine and Immunotherapy Center
Massachusetts General Hospital55 Fruit StreetGray Building, 7-730Boston, MA 02114E-mail us
Back to Top